Published: 23 January 2020
Author(s): Milo Gatti, Matteo Bianchin, Emanuel Raschi, Fabrizio De Ponti
Issue: January 2020
Section: Original article

Systemic fluoroquinolones remain commonly prescribed broad-spectrum antibiotics, both in hospital and outpatient settings, despite rising resistance rates [1–7]. Since their approval, fluoroquinolones were associated with serious adverse events (AEs), such as Clostridium difficile infection, fatal arrhythmia due to QT prolongation, hepatotoxicity, severe haemolytic-uremic syndrome and dysglycemia, leading to the market withdrawal of some compounds (temafloxacin, trovafloxacin, grepafloxacin and gatifloxacin) [8–13].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.